Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir in HTLV-1 Associated Myelopathy
NCT02655471Phase 1Completed
- Sponsor
- Universidad Peruana Cayetano Heredia
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of raltegravir in HTLV-1-associated myelopathy (HAM), sponsored by Universidad Peruana Cayetano Heredia. Primary endpoint: Measure of proviral load at 48 weeks. Started Jul 2017; status: completed.
02
Drugs
raltegravir
03
Conditions
HTLV-1-associated myelopathy (HAM)
Beyond the preview
Go deeper on NCT02655471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02655471.